A Phase II Trial of Docetaxel, Thalidomide, Prednisone and Bevacizumab in Patients With Androgen-Independent Prostate Cancer.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Bevacizumab; Docetaxel; Prednisone; Thalidomide
- Indications Prostate cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 20 Apr 2018 Biomarkers information updated
- 09 Jan 2012 Planned end date changed from 1 Dec 2011 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 09 Jan 2012 Planned end date changed from 1 Dec 2011 to 1 Dec 2014 as reported by ClinicalTrials.gov.